TB-500 and thymosin beta-4: clarify the names and evidence

Thymosin beta-4 and TB-500 are not the same thing. Full-length thymosin beta-4 has been studied in laboratory, animal and limited human research, mostly for eye and skin uses. Those findings do not establish that the TB-500 fragment treats injuries. This page gives no dosing and does not recommend or advise against any product.

Quick answer

Thymosin beta-4 and TB-500 are not the same thing. Full-length thymosin beta-4 has been studied in laboratory, animal and limited human research, mostly for eye and skin uses. Those findings do not establish that the TB-500 fragment treats injuries. This page gives no dosing and does not recommend or advise against any product.

Sorting out the names

  • Thymosin beta-4 (TB-4): the full-length peptide that occurs in the body and that researchers have studied.
  • TB-500 is a seven-amino-acid fragment of thymosin beta-4. A 2026 narrative review says it is frequently confused with the full-length peptide, although no validated biologic or clinical equivalence has been shown.

What the human evidence looks like

RGN-259 trial

RGN-259 trial

The 2026 review says TB-4 has broader experimental and human experience in eye, skin and heart applications, while direct musculoskeletal evidence is limited to cell and rodent studies. It says non-orthopaedic findings cannot establish musculoskeletal efficacy or safety. Source: narrative review, 2026.

One example of human research is a randomized, placebo-controlled, double-masked phase 3 trial of 0.1% thymosin beta-4 eye drops (RGN-259) in people with neurotrophic keratopathy, an eye disease. Complete healing at 4 weeks occurred in 6 of 10 treated participants and 1 of 8 placebo participants (p = 0.0656, which the authors call a trend). The trial was small, tested eye drops, and did not test injections or any musculoskeletal use. Source: RGN-259 phase 3 trial, 2022.

Safety evidence and limits

For the TB-500 fragment, unresolved safety questions include immune reactions, aggregation and peptide-related impurities. Adequate human safety information is lacking; uncertainty is not evidence of safety.

The 2026 review raises concerns about identity, purity, concentration, sterility and manufacturing consistency. Human evidence does not establish an injury-recovery benefit.

If you are considering a product

Tell your clinician the exact product name, who made it and what label or test information came with it, and ask what established options exist. If you compete in sport, ask about anti-doping rules.

What this does not establish

The eye-drop trial does not show that thymosin beta-4 or TB-500 works or is safe as an injection. Lack of human data for TB-500 is not evidence of harm or of safety. Marketplace names may not match what is in a vial.

FAQs

What is TB-500 and thymosin beta-4? Thymosin beta-4 is a naturally occurring peptide. TB-500 is described as a seven amino-acid fragment of it, and the two should not be assumed to be equivalent.

What does human research show about TB-500 and thymosin beta-4? Human research on full-length thymosin beta-4 is limited and mostly concerns eye, skin and heart conditions. These studies do not establish benefits for the TB-500 fragment.

What safety questions remain about TB-500 and thymosin beta-4? Immune reactions, impurities, product identity and the lack of adequate human safety data remain concerns.

Sources

  1. Investigational peptides in orthopaedic practice: BPC-157, thymosin beta-4 and TB-500, 2026
  2. RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy, phase 3, 2022
  3. Primary safety information on peptide ingredients

Source methods and reading limits

Sources checked against Europe PMC abstracts and product-label text: November 17, 2026. Full text was not read for abstract-only claims. Source dates and reading limits are recorded with the supporting references.